Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients

References

• Tausch E, Mertens D, Stilgenbauer S. Advances in treating chronic lymphocytic leukemia. F1000 Prime Rep. 2014;6:65. doi:10.12703/P6-65
   PubMedGoogle Scholar
• Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014;32:3039–3047. doi:10.1200/JCO.2014.55.826225049322
   PubMed Web of Science ®Google Scholar
• Cuneo A, Cavazzini F, Ciccone M, et al. Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med. 2014;3:555–564. doi:10.1002/cam4.22624648042
   PubMed Web of Science ®Google Scholar
• Fischer K, Hallek M. Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program. 2017;8:338–345.
   Google Scholar
• Furman RR. Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:77–81.21239774
   PubMedGoogle Scholar
• Zenz T, Fröhling S, Mertens D, Döhner H, Stilgenbauer S. Moving from prognostic to predictive factors in chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol. 2010;23:71–84.20620972
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukemia. Nat Rev Dis Primers. 2017;3:17008. doi:10.1038/nrdp.2017.828179635
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–460.25908509
   PubMed Web of Science ®Google Scholar
• Cramer P, Hallek M, Eichhorst B. State-of-the-art treatment and novel agents in chronic lymphocytic leukemia. Oncol Res Treat. 2016;39:25–32.26890007
   PubMed Web of Science ®Google Scholar
• Yeh CH, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15:37. doi:10.1186/s12943-016-0518-227179712
   PubMed Web of Science ®Google Scholar
• Fischer SE. RNA interference and microRNA-mediated silencing. Curr Protoc Mol Biol. 2015;112:1–5. doi:10.1002/0471142727.mb2601s112
   Google Scholar
• Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res. 2011;717:1–8. doi:10.1016/j.mrfmmm.2011.03.00921458467
   PubMed Web of Science ®Google Scholar
• MacFarlane LM, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11:537–561. doi:10.2174/13892021079317589521532838
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad Sci USA. 2005;102:13944–13949. doi:10.1073/pnas.050665410216166262
   PubMed Web of Science ®Google Scholar
• Szymczyk A, Chocholska S, Macheta A, Szczepanek D, Hus M, Podhorecka M. Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease. Oncotarget. 2018;9:19136–19146. doi:10.18632/oncotarget.2492729721189
   PubMedGoogle Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159. doi:10.1006/abio.1987.99992440339
   PubMed Web of Science ®Google Scholar
• Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179. doi:10.1093/nar/gni17816314309
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456. doi:10.1182/blood-2007-06-09390618216293
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997.8652811
   PubMed Web of Science ®Google Scholar
• Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res. 2004;28:429–442. doi:10.1016/j.leukres.2003.08.01715068894
   PubMed Web of Science ®Google Scholar
• Seiffert M, Dietrich S, Jethwa A, Glimm H, Lichter P, Zenz T. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1023–1031. doi:10.3109/10428194.2011.63163822023519
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174. doi:10.1016/S0140-6736(10)61381-520888994
   PubMed Web of Science ®Google Scholar
• Kobylinska A, Bednarek J, Blonski JZ, et al. In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. Oncol Rep. 2006;16:1389–1395.17089066
   PubMed Web of Science ®Google Scholar
• Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114:2589–2597. doi:10.1182/blood-2009-05-22407119643983
   PubMed Web of Science ®Google Scholar
• Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298–1307. doi:10.1016/j.cub.2007.06.06817656095
   PubMed Web of Science ®Google Scholar
• Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–752. doi:10.1016/j.molcel.2007.05.01017540599
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130–1134. doi:10.1038/nature0593917554337
   PubMed Web of Science ®Google Scholar
• Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–1593. doi:10.4161/cc.6.13.443617554199
   PubMed Web of Science ®Google Scholar
• Ferracin M, Zagatti B, Rizzotto L, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer. 2010;9:123. doi:10.1186/1476-4598-9-25420504344
   PubMed Web of Science ®Google Scholar
• Castejón R, Yebra M, Citores M-J, Villarreal M, García-Marco JA, Vargas JA. Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:593–603. doi:10.1080/1042819090278066919373658
   PubMed Web of Science ®Google Scholar
• Sieklucka M, Pozarowski P, Bojarska-Junak A, Hus I, Dmoszynska A, Rolinski J. Apoptosis in B-CLL: the relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome. Oncol Rep. 2008;19:1611–1620.18497973
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Klimek P, Chocholska S, et al. The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia. Eur J Clin Pharmacol. 2015;71:1121–1127. doi:10.1007/s00228-015-1893-026141594
   PubMed Web of Science ®Google Scholar
• Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues - correlation with clinical course. Leukemia. 1998;12:1230–1235.9697877
   PubMed Web of Science ®Google Scholar
• Żołnierczyk JD, Borowiak A, Błoński JZ, et al. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent. Pharmacol Rep. 2013;65:460–475.23744431
   PubMed Web of Science ®Google Scholar